妇科癌症中的外体非编码RNA:对治疗耐药性和生物标志物的影响
Changfen Xu1, Peiyao Xu1, Jiaqi Zhang1
1Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
Frontiers in oncology
|May 13, 2024
概括
外体非编码RNAs (ncRNAs) 在妇科癌症药物耐药性中发挥作用. 这些分子也可以作为生物标志物用于早期检测和预后在卵巢,宫和子宫内膜癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 妇科癌症 (卵巢,子宫,子宫内膜) 是导致妇女死亡的主要原因.
- 治疗耐药性显著阻碍治疗疗效,其分子机制尚不清楚.
- 外体,纳米级囊泡,通过像ncRNAs这样的封装分子调解细胞间的通信.
研究的目的:
- 审查外体ncRNAs在妇科瘤耐药性的生物学作用和机制.
- 探索外体ncRNAs作为妇科癌症液体活检生物标记物的潜力.
主要方法:
- 对外体ncRNA和妇科癌症耐药性研究的文献综述.
- 对外体ncRNA参与瘤发生,转移和瘤微环境调节的分析.
- 对外体ncRNAs作为诊断和预后标记物的评估.
主要成果:
- 外体ncRNAs参与细胞间通信,并影响瘤进展和药物耐药性.
- 特定的外体ncRNAs可以调节在妇科癌症中对化疗和辐射的敏感性.
- 外体ncRNAs显示出作为妇科癌症检测和结果预测的非侵入性生物标志物的承诺.
结论:
- 外体ncRNAs是妇科癌症治疗耐药性的关键调解者.
- 向外体ncRNAs是一个潜在的治疗策略.
- 外体ncRNA具有作为妇科恶性瘤液体活检生物标志物的显著潜力.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
11.1K
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
